Literature DB >> 29538091

Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.

Anne M Stowman1, Alexandra W Hickman2, Ileana S Mauldin3, Adela Mahmutovic3, Alejandro A Gru4, Craig L Slingluff3.   

Abstract

Desmoplastic melanomas (DM) have unique and challenging clinical presentations and histomorphology. A characteristic feature is the presence of scattered lymphoid aggregates. However, the nature of these aggregates is not defined. We hypothesized that they may be tertiary lymphoid structures (TLS), and may be associated with programmed death ligand 1 (PD-L1) expression. We searched our tissue database for 'pure' DMs and for scars as control tissues, collected clinical information, and reviewed H&E histology. We performed multispectral imaging after staining for CD8, CD20, PNAd, FoxP3, CD83, and Ki67, and assessed PD-L1 expression by immunohistochemistry. Pure DM samples were evaluable in 11 patients. All had desmoplastic stroma and lymphoid aggregates on H&E. The lymphoid aggregates of eight of the 11 (72%) DM samples and only three of the 11 scars contained features of TLS, defined as distinct clusters of B cells and CD8 T cells, CD83 dendritic cells in T-cell zones, and PNAd vasculature resembling high endothelial venules. PD-L1 was expressed by at least 1% of melanoma cells in six and by at least 5% of immune cells in 10 of the 11 DM samples. We found that most lymphoid aggregates in DM are organized, classical TLS. PD-L1 expression was detected in most cases and was highest in two cases of DM with TLS. However, low PD-L1 expression in some cases suggests that some DM cells may be unresponsive to interferon-γ. TLS support antigen presentation and T-cell responses in chronic inflammation and cancer. Their presence in DM likely reflects an adaptive immune response, which may be enhanced with immune therapies.

Entities:  

Mesh:

Year:  2018        PMID: 29538091      PMCID: PMC5912978          DOI: 10.1097/CMR.0000000000000439

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  34 in total

1.  Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.

Authors:  Andrea Ladányi; Judit Kiss; Beáta Somlai; Katalin Gilde; Zsuzsanna Fejos; Anita Mohos; István Gaudi; József Tímár
Journal:  Cancer Immunol Immunother       Date:  2007-02-06       Impact factor: 6.968

2.  Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma.

Authors:  Timothy M Pawlik; Merrick I Ross; Victor G Prieto; Matthew T Ballo; Marcella M Johnson; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

3.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

4.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

5.  Desmoplastic malignant melanoma and its variants. A study of 45 cases.

Authors:  S Jain; P W Allen
Journal:  Am J Surg Pathol       Date:  1989-05       Impact factor: 6.394

6.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Authors:  Joseph M Obeid; Gulsun Erdag; Mark E Smolkin; Donna H Deacon; James W Patterson; Leiping Chen; Timothy N Bullock; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

7.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Authors:  Jérémy Goc; Claire Germain; Thi Kim Duy Vo-Bourgais; Audrey Lupo; Christophe Klein; Samantha Knockaert; Luc de Chaisemartin; Hanane Ouakrim; Etienne Becht; Marco Alifano; Pierre Validire; Romain Remark; Scott A Hammond; Isabelle Cremer; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

Review 8.  Tertiary lymphoid organs in infection and autoimmunity.

Authors:  Katrijn Neyt; Frédéric Perros; Corine H GeurtsvanKessel; Hamida Hammad; Bart N Lambrecht
Journal:  Trends Immunol       Date:  2012-05-21       Impact factor: 16.687

9.  Lymphoid neogenesis in melanoma: What does it tell us?

Authors:  Nicolas van Baren; Jean-François Baurain; Pierre G Coulie
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Authors:  A Hunter Shain; Maria Garrido; Thomas Botton; Eric Talevich; Iwei Yeh; J Zachary Sanborn; Jongsuk Chung; Nicholas J Wang; Hojabr Kakavand; Graham J Mann; John F Thompson; Thomas Wiesner; Ritu Roy; Adam B Olshen; Alexander Gagnon; Joe W Gray; Nam Huh; Joe S Hur; Klaus J Busam; Richard A Scolyer; Raymond J Cho; Rajmohan Murali; Boris C Bastian
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more
  15 in total

1.  Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes.

Authors:  Max O Meneveau; Zeyad T Sahli; Kevin T Lynch; Ileana S Mauldin; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

Review 3.  B cells and antibody production in melanoma.

Authors:  Jessica Da Gama Duarte; Janique M Peyper; Jonathan M Blackburn
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

4.  Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

Authors:  Teng He; Zhixing Hao; Mingjie Lin; Zhongwei Xin; Yongyuan Chen; Wei Ouyang; Qi Yang; Xiaoke Chen; Hui Zhou; Wanying Zhang; Pin Wu; Feng Xu
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

Review 5.  Tertiary lymphoid structures in cancer - considerations for patient prognosis.

Authors:  Luis Munoz-Erazo; Janet L Rhodes; Valentine C Marion; Roslyn A Kemp
Journal:  Cell Mol Immunol       Date:  2020-05-15       Impact factor: 11.530

6.  Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value.

Authors:  K Li; Q Guo; X Zhang; X Dong; W Liu; A Zhang; Y Li; J Yan; G Jia; Z Zheng; W Tang; L Pan; M An; B Zhang; S Liu; B Fu
Journal:  Clin Exp Immunol       Date:  2019-11-08       Impact factor: 4.330

Review 7.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

8.  STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.

Authors:  Manoj Chelvanambi; Ronald J Fecek; Jennifer L Taylor; Walter J Storkus
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

9.  Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.

Authors:  Kevin T Lynch; Samuel J Young; Max O Meneveau; Nolan A Wages; Victor H Engelhard; Craig L Slingluff; Ileana S Mauldin
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

10.  A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration.

Authors:  Franziska Werner; Christine Wagner; Martin Simon; Katharina Glatz; Kirsten D Mertz; Heinz Läubli; Johannes Griss; Stephan N Wagner
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.